46411.1 IP-LS

Résumé

Development of an innovative therapy for ANCA- associated vasculitis (AAV)

Textes supplémentaires

Abstract

AAV is a life-threatening autoimmune disease with no effective available treatment. 60% of patients are refractory to therapy or relapse within a year. This project aims to address this unmet medical need substantially advancing treatment by developing novel compounds targeting disease pathogenesis.

Participants

Valentina Aureggi

Wirtschaftspartner

vaureggi@blackpearlth.com

Black Pearl Therapeutics AG CHE-328.771.324 Valentina Aureggi c/o Andrea Cavalli, Albisriederstrasse 184B 8047 Zürich ZH CH

Mariagrazia Uguccioni

Kontaktperson

mariagrazia.uguccioni@irb.usi.ch

Istituto di Ricerca in Biomedicina Mariagrazia Uguccioni via Francesco Chiesa 5 6500 Bellizona TI CH

Détails du projet

Office de recherche: INNOSUISSE
Statut du projet: Abgeschlossen
Type de projet: Forschungsprojekt
Date de début: 2020-08-31
Date de fin: 2023-08-31
Coûts totaux approuvés: CHF 472302.36
Section: 60 Life Sciences
Domaine politique NABS: Industrielle Produktivität und Technologie

Disciplines de recherche

B007 Medicine (human and vertebrates) 100.0%